Literature DB >> 27841423

Improving selective targeting to macrophage subpopulations through modifying liposomes with arginine based materials.

Lilusi Ma1, Hannah C Bygd1, Kaitlin M Bratlie2.   

Abstract

The effects of surface modifications on liposomes using a library of arginine derivatives for improved drug delivery were examined. Both unmodified and modified liposomes were tested for their drug delivery properties and propensity for internalization by macrophages. All materials were characterized by dynamic light scattering (DLS) and zeta potential. The resulting liposomes were able to encapsulate doxorubicin with a loading efficiency greater than 90% and cumulative releases of less than 15% after 144 h. The internalization of these particles was examined by loading the liposomes with fluorescein or doxorubicin to test internalization through fluorescence level and half maximal inhibitory concentration (IC50), respectively. RAW 264.7 macrophages were activated with lipopolysaccharide (LPS) or interleukin-4 (IL-4) to induce M1- or M2-like phenotypes. Naïve macrophages were also studied. Most modified liposomes enhanced the cytotoxicity of doxorubicin compared to unmodified liposomes. Macrophage phenotype was also observed to influence the cytotoxicity of doxorubicin entrapped in modified liposomes, with some samples enhancing the cytotoxicity in LPS stimulated macrophages and some enhancing toxicity in IL-4 stimulated cells.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27841423     DOI: 10.1039/c6ib00133e

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  1 in total

1.  A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers.

Authors:  Poonam Parashar; Chandra Bhushan Tripathi; Malti Arya; Jovita Kanoujia; Mahendra Singh; Abhishek Yadav; Shubhini A Saraf
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.